Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8729488 | 0.89 | CHRM5 (0.79) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL23464917 | 0.86 | CHRM5 (0.75) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL18743787 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL7721235 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL983664 | 0.83 | CHRM5 (0.71) | CHRM5CHRM3ALDH1A1SIGMAR1SMN1; SMN2 | |
| SCHEMBL13417680 | 0.82 | CHRM5 (0.70) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL1019855 | 0.80 | CHRM5 (0.67) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL2007992 | 0.80 | CHRM5 (0.67) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL24739921 | 0.80 | CHRM5 (0.67) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 | |
| SCHEMBL18811738 | 0.79 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1SIGMAR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040023977-A1 | Process for making substituted thiazolyl-amino pyrimidinyl | LARSEN ROBERT D (US) | 2004-02-05 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3562487-B1 | METALLOENZYME INHIBITOR COMPOUNDS | JI XING PHARMACEUTICALS HONG KONG LTD (HK) | 2023-11-29 | — | — | EP | disclosed |
| US-20230350305-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND TREATMENT LIQUID | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230350305-A1 | MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND TREATMENT LIQUID | FUJIFILM CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-0220939-A1 | 6-(1-Carbamoyl-1-hydroxymethyl)penicillanic-acid derivatives | PFIZER INC. (US) | 1987-05-06 | — | — | EP | disclosed |
| US-4610984-A | CEREBRAL INSUFFICIENCY | CASSELLA AKTIENGESELLSCHAFT (DE) | 1986-09-09 | — | — | US | disclosed |
| US-4604463-A | ANTITUMOR AGENTS | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1986-08-05 | — | — | US | disclosed |
| US-4582833-A | HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0171636-A1 | Pharmacologically active piperazino derivatives and the process for their preparation | RAVIZZA S.p.A. (IT) | 1986-02-19 | — | — | EP | disclosed |
| EP-0137145-A1 | New camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-4500531-A | CENTRAL NERVOUS SYSTEM STIMULANTS | DELALANDE S.A. (FR) | 1985-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023977-A1 | Process for making substituted thiazolyl-amino pyrimidinyl | TYK2, ERBB2, JAK2 | CHRM5 4543/4885CHRM3 4480/4885ALDH1A1 2935/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | CHRM5 2033/4885CHRM3 1616/4885ALDH1A1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.